Avalon
Log In
Contact

Analytics

Transform Cardiometabolic Care

with Cost-Efficient, Risk-Aligned GLP-1 Management

Learn More

GLP-1s are highly effective, but at what cost?

GLP-1 therapies are revolutionizing cardiometabolic care. Avalon unifies lab, medical, and pharmacy data to deliver clear, actionable insights—helping payers and providers navigate complex conditions like cardio-kidney metabolic syndrome and make the most of every treatment decision.

$26.6B

GLP-1 therapy revenue in 2023

400%

growth through 2030 (25.88% CAGR)

$133B

GLP-1 spend forecasts through 2030

Traditional methods fall short.

Rising GLP-1 costs are putting pressure on payers, driving tough coverage decisions. Relying solely on BMI-based policies falls short of advancing health equity, prioritizing high-risk patients, and closing access gaps.

We take a comprehensive, technology-driven approach to GLP-1 therapy management.

Our innovative, data-driven approach utilizes advanced technology and lab data to optimize resource allocation. This leads to better patient care, improved outcomes, reduced costs, and greater value for your GLP-1 investments.

Risk
Stratification

We evaluate health data holistically, focusing on A1C levels, lipid panels, and cardiovascular risks to identify patients likely to benefit.

Focused Allocation

High-need patients receive focus, ensuring resources are allocated where they will have the most significant impact.

Automated Process

Designed to ease administrative burdens like prior authorizations, our approach helps providers and patients access care faster and with less friction.

Real-World Challenges Speak Volumes

A national health plan faced skyrocketing costs due to inefficient allocation of GLP-1 therapies. Traditional BMI-only policies meant lower-risk individuals disproportionately received treatments while high-risk candidates were underserved.

Low risk patients with diabetes are 3 times more likely to get treatment than high risk patients
Low risk patients without diabetes are 14 times more likely to get treatment than high risk patients

The 2025 Lab Trend Report is available

Download Now

The Takeaway:

Targeting optimization with data and technology ensures resources benefit those most in need, enhancing outcomes for the broader patient population.

Turning Data into Better Cardiometabolic Health

The Glow Up Podcast: Revolutionizing Healthcare with Lab Data and AI

Listen Now

01

Patient Evaluation

Advanced analytics assess and stratify patients based on overall health risks.

02

Resource Allocation

Elevate GLP-1 coverage for patients with the highest predicted benefit.

03

Streamline

For those patients who meet established criteria, simplify the prior authorization process.

04

Outcome Monitoring

Track results to improve metrics like glucose, cardio-metabolic health, and admissions.

05

Refinement

Use data insights to iterate and optimize coverage policies for sustained impact.

Benefits you can expect

Unlock meaningful improvements across care, cost, and quality with these key advantages:

Maximized ROI on GLP-1 Spend

Balance cost control with improved care by channeling resources to the right patients.

Boosted HEDIS Scores

Achieve success in key quality metrics to elevate your organization’s performance.

Population Health Management

Targeted interventions lower hospitalization rates, slow disease progression, and enhance outcomes.

Enhanced Cost Efficiency

Reduce administrative work and overspending while providing high-value care where it matters.

Take the first step toward smarter coverage

Simplify GLP-1 therapy management. Leverage technology and data for unmatched value. Align policies with measurable outcomes to ensure equitable and high-quality care.

Let’s Talk